Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostate Cancer: An EORTC Feasibility Study
- 1 November 2003
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 44 (5) , 505-511
- https://doi.org/10.1016/s0302-2838(03)00375-0
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft modelThe Prostate, 2000
- Intermittent androgen suppression in the management of prostate cancerUrology, 1999
- Intermittent androgen suppression in the treatment of prostate cancer: A preliminary reportUrology, 1995
- Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer, 1993
- Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancerCancer, 1992
- The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate CancerJournal of Urology, 1992
- Prostate Specific Antigen in Hormonally Treated Stage D2 Prostate Cancer: Is it always an Accurate Indicator of Disease Status?Journal of Urology, 1991
- Experimental Treatment of Prostatic Cancer by Intermittent Hormonal TherapyJournal of Urology, 1987
- Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold conceptThe Prostate, 1987
- Intermittent endocrine therapy for advanced prostate cancerCancer, 1986